Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Company Financials: Orthopaedics and Spine

Here we present final 4Q12 and 2012 revenue for remaining companies, as well as Biomet’s latest fiscal quarter. Exhibit 1 displays orthopaedic sales increases by product segment for 2012 vs. 2011 unless otherwise noted. Performance highlights that follow pertain to a blend of 4Q12 and 2012.

Exhibit 1: Orthopaedic Sales1 Increases by Product Segment: 2012 vs. 2011
(Click on chart for larger image) 

BZ June_Financials


Alphatec Spine
$196.3MM, +1% (U.S. $130.5MM, -3%; ex-U.S. $65.8MM, +7%: Japan ~$29MM, +>20%)
4Q12 revenue: $52.7MM, +8% (U.S. $34MM, +4%; ex-U.S. $18.7MM, +16%)

  • Received regulatory clearance in Japan to market NOVELA PEEK Spinal Spacers
  • 2013 product launches: Pegasus anterior cervical interbody device; MIS ILLICO screw fixation; relaunch of Solis (U.S. late 2Q/early 3Q)

$244.9MM, +3% (U.S. $156.9MM, +3%; ex-U.S. $87.9MM, +2%)

  • Sports Medicine $235.7MM, +3% (U.S. $155.1MM, +4%; ex-U.S. $80.6MM, +2%)
  • Other (includes Spine) $9.1MM, -6% (U.S. $1.8MM, -34%; ex-U.S. $7.3MM, +5%)

4Q12 revenue: $66.1MM, +2% (U.S. $41.8MM, -2%; ex-U.S. $24.3MM, +9%)

  • Sports Medicine $63.5MM, +2% (U.S. $41.2MM, -2%; ex-U.S. $22.2MM, +9%)
  • Other (includes Spine) $2.5MM, +3% (U.S. $0.5MM, -13%; ex-U.S. $2.0MM, -17%)
  • Acquisition of Eleven Blade Solutions closed 1Q13 following FDA clearance of products
  • 2H13 product launches include Coblation for anterior cruciate ligament reconstruction